Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

Exclusion Criteria

• •ALT/AST \> 3 ULN, BUN/Cr \> 1.5 ULN.
• •Skin lesions were limited to head，face and skin folds.
• •Women who are pregnant, breast-feeding, or planning to become pregnant.
• •Known to be allergic to active ingredients or any of the components of the drug.
• •Alcoholic, or regular use of Chinese herbs or sedatives, sleeping pills, tranquilizers and other addictive drugs.
• •Subjects who have other conditions that may interfere with the evaluation of the efficacy of psoriasis and/or other serious skin diseases other than psoriasis.
• •Subjects who have serious diseases of the central nervous system, cardiovascular system, kidney, liver, digestive tract, respiratory system, metabolism and skeletal muscle system.
• •Subjects who were considered unsuitable to participate in the study by the investigators.
• •Received uv phototherapy, photochemotherapy, or systemic therapy (e.g., systemic glucocorticoid, methotrexate, retinoic acid, or cyclosporine) within 4 weeks prior to baseline visit.
• •Received topical anti-psoriasis therapy (including topical glucocorticoids, retinoids, vitamin D analogues, or calcineurin inhibitors) within 2 weeks prior to baseline visit, except where the site of administration was not the target lesion after enrollment.